GeoVax Labs, Inc. (GOVX), a company focused on cancer and infectious diseases, announced on Tuesday that it has inked a deal with an institutional investor to sell 1.700 million shares at $5 per share in a registered direct offering priced above-the-market.
In addition, in a concurrent private placement, the drug maker will issue to the investor warrants to purchase up to 1.700 million shares with an exercise price of $5 per share.
The gross proceeds to the company from the offering are expected to be around $8.5 million.
The company intends to use the net proceeds for working capital and general corporate purposes.
The closing of the offering is expected to occur on or about August 21.
Roth Capital Partners is acting as the exclusive placement agent for the offering.
GOVX was trading down by 25.59 percent at $5.32 in the pre-market trade on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.